Targeting the adaptive molecular landscape of castration-resistant prostate cancer
Castration and androgen receptor (AR) pathway inhibitors induce profound and sustained responses in advanced prostate cancer. However, the inevitable recurrence is associated with reactivation of the AR and progression to a more aggressive phenotype termed castration-resistant prostate cancer (CRPC)...
Main Authors: | Wyatt, Alexander W, Gleave, Martin E |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley & Sons, Ltd
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520654/ |
Similar Items
-
Novel non-AR therapeutic targets in castrate resistant prostate cancer
by: Toren, Paul J., et al.
Published: (2013) -
Targeting molecular resistance in castration-resistant prostate cancer
by: Chandrasekar, Thenappan, et al.
Published: (2015) -
The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
by: Grasso, Catherine S., et al.
Published: (2012) -
Targeting hexokinase 2 in castration-resistant prostate cancer
by: Deng, Yibin, et al.
Published: (2015) -
Targeting the MLL complex in castration resistant prostate cancer
by: Malik, Rohit, et al.
Published: (2015)